Madrigal Pharmaceuticals Target Price

Where could MDGL trade next? Consensus target price: $710.

Get informed when a big investor buys or sells

+ Follow

Share Price

$432.79

Average Target Price

$706.86

63.3% upside

7 analysts in the last 4 months

High: $962 | Low: $587

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-10-29	B.Riley FinancialMayank Mamtani	$670	54.8% upside
2026-10-14	UBSAshwani Verma	$735	69.8% upside
2026-09-24	Goldman Sachs	$704	62.7% upside
2026-08-04	Wolfe Research	$605	39.8% upside
2026-07-31	Barclays	$962	122.3% upside
2026-07-29	Canaccord Genuity	$587	35.6% upside
2026-07-27	Wells Fargo	$685	58.3% upside
2026-06-11	Morgan Stanley	$542	25.2% upside
2026-05-13	Truist Financial	$709	63.8% upside
2026-05-07	Canaccord Genuity	$578	33.6% upside
2026-05-07	Evercore ISI	$649	50% upside
2026-01-27	Barclays	$964	122.7% upside
2026-01-14	Goldman SachsAndrea Tan	$571	31.9% upside
2026-01-06	Wolfe ResearchAndy Chen	$579	33.8% upside
2025-12-19	Piper SandlerYasmeen Rahimi	$900	108% upside
2025-12-19	UBS	$900	108% upside
2025-11-21	H.C. Wainwright	$620	43.3% upside
2025-11-20	OppenheimerJay Olson	$650	50.2% upside
2025-11-19	Truist Financial	$640	47.9% upside
2025-11-05	JMP Securities	$527	21.8% upside
2025-10-15	Piper Sandler	$540	24.8% upside
2025-10-14	Truist Financial	$580	34% upside
2025-10-10	OppenheimerJay Olson	$590	36.3% upside
2025-05-02	Canaccord GenuityEdward Nash	$420	3% downside
2024-05-29	Piper SandlerYasmeen Rahimi	$336	22.4% downside
2024-05-09	H.C. WainwrightEd Acre	$390	9.9% downside
2024-03-19	Evercore ISILiisa Bayko	$405	6.4% downside
2024-03-15	UBSEliana Merle	$410	5.3% downside
2024-03-15	JefferiesAkash Tewari	$400	7.6% downside
2024-03-15	H.C. WainwrightEd Acre	$425	1.8% downside
2024-03-15	JMP SecuritiesJonathan Wolleben	$397	8.3% downside
2024-03-15	B.Riley FinancialMayank Mamtani	$270	37.6% downside
2023-01-05	JMP Securities	$390	9.9% downside
2022-12-21	UBS	$337	22.1% downside
2022-12-20	H.C. Wainwright	$225	48% downside
2022-12-20	Oppenheimer	$250	42.2% downside
2022-12-20	Goldman Sachs	$375	13.4% downside
2022-12-20	JMP Securities	$312	27.9% downside
2022-12-20	Leerink Partners	$315	27.2% downside
2021-08-06	BMO CapitalMatthew Luchini	$111	74.4% downside
2021-05-20	Goldman SachsAndrea Tan	$195	54.9% downside
2021-05-06	Wells FargoDerek Archila	$130	70% downside

Madrigal Pharmaceuticals (MDGL) FAQ

Madrigal Pharmaceuticals (MDGL) currently reports a target price of $710. Use the charts on this page to explore Madrigal Pharmaceuticals's target price history and peer comparisons.

Analysts' average 12-month price target for Madrigal Pharmaceuticals is $710, about 63.3% upside from the current share price of $432.79. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $710, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Madrigal Pharmaceuticals, and consider following MDGL for alerts when major investors trade the stock.

Madrigal Pharmaceuticals is classified in the Healthcare sector. On target price, it currently shows $710. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MDGL with unrelated industries.